The FASEB Journal · 2002 · 1K citations · 25 references
PharmacyMolecular PharmaceuticsPharmaceuticsDrug DeliveryGene DeliveryNanoparticle Drug DeliveryLysosomal TraffickingNanocarriers For TherapeuticsNanomaterials For Drug DeliveryNanomedicineNanoparticle Delivery SystemsPolymeric NanoparticlesBiodegradable Drug CarriersBiodegradable Polymeric NanoparticlesEndolysosomal Escape PathwaysGene Delivery NanocarriersLysosomal Sequestration Of NanoparticlesNanoparticle DeliveryNanoparticlesPoly(lactic-co-glycolic Acid) Nanoparticles
The endo-lysosomal escape of drug carriers is crucial to enhancing the efficacy of their macromolecular payload, especially the payloads that are susceptible to lysosomal degradation. Current vectors that enable the endo-lysosomal escape of macromolecules such as DNA are limited by their toxicity and by their ability to carry only limited classes of therapeutic agents. In this paper, we report the rapid (<10 min) endo-lysosomal escape of biodegradable nanoparticles (NPs) formulated from the copolymers of poly(DL-lactide-co-glycolide) (PLGA). The mechanism of rapid escape is by selective reversal of the surface charge of NPs (from anionic to cationic) in the acidic endo-lysosomal compartment, which causes the NPs to interact with the endo-lysosomal membrane and escape into the cytosol. PLGA NPs are able to deliver a variety of therapeutic agents, including macromolecules such as DNA and low molecular weight drugs such as dexamethasone, intracellularly at a slow rate, which results in a sustained therapeutic effect. PLGA has a number of advantages over other polymers used in drug and gene delivery including biodegradability, biocompatibility, and approval for human use granted by the U.S. Food and Drug Administration. Hence PLGA is well suited for sustained intracellular delivery of macromolecules.
25
Vladimir P. Torchilin, Ram Rammohan, Volkmar Weissig et al. · Proceedings of the National Academy of Sciences · 2001 · 779 citations · Full text